Literature DB >> 2729936

Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits.

M G Täuber1, S Kunz, O Zak, M A Sande.   

Abstract

We examined the influence of several pharmacokinetic parameters on cure rates in rabbits with experimental pneumococcal meningitis. When the duration of treatment was kept constant, cure rates improved as the individual dose of ampicillin was increased. On the other hand, when four doses of ampicillin at 60 mg/kg of body weight, producing peak concentrations in cerebrospinal fluid (CSF) of approximately 40 times the MBC, were administered at intervals of 24 instead of 4 h and the duration of therapy was thus prolonged from 12 to 72 h, cure rates also increased (85 versus 25%; P less than 0.01). These high cure rates were achieved even though bacterial titers in CSF 24 h after the first dose had reached levels similar to those present at the beginning of therapy. Cure in these animals was explained by the fact that the second ampicillin dose reduced bacterial titers in CSF significantly more than did the first dose (5.2 versus 2.5 log10 CFU/ml; P less than 0.02). The clinical relevance of these observations remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729936      PMCID: PMC172452          DOI: 10.1128/AAC.33.4.418

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Acute bacterial meningitis: an analysis of factors influencing prognosis.

Authors:  G R Hodges; R L Perkins
Journal:  Am J Med Sci       Date:  1975 Nov-Dec       Impact factor: 2.378

2.  Factors influencing the therapy of experimental Proteus mirabilis meningitis in rabbits.

Authors:  L J Strausbaugh; M A Sande
Journal:  J Infect Dis       Date:  1978-03       Impact factor: 5.226

3.  The influence of fever on the development of experimental Streptococcus pneumoniae meningitis.

Authors:  M A Sande; E R Sande; J D Woolwine; C J Hackbarth; P M Small
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

4.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  Landmark perspective: The impact of penicillin on the treatment of meningitis.

Authors:  M G Täuber; M A Sande
Journal:  JAMA       Date:  1984-04-13       Impact factor: 56.272

6.  Effects of temperature on antimicrobial susceptibility of bacteria.

Authors:  P A Mackowiak; M Marling-Cason; R L Cohen
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

7.  Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.

Authors:  W M Scheld; M A Sande
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Experimental pneumococcal meningitis: role of leukocytes in pathogenesis.

Authors:  J D Ernst; J M Decazes; M A Sande
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

10.  Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the postantibiotic effect in vivo.

Authors:  M A Sande; O M Korzeniowski; G M Allegro; R O Brennan; O Zak; W M Scheld
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb
View more
  8 in total

1.  Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.

Authors:  I Lutsar; A Ahmed; I R Friedland; M Trujillo; L Wubbel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae.

Authors:  Y S Kim; Q Liu; L L Chow; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Once-daily gentamicin therapy for experimental Escherichia coli meningitis.

Authors:  A Ahmed; M M París; M Trujillo; S M Hickey; L Wubbel; S L Shelton; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

4.  Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  A Ahmed; H Jafri; I Lutsar; C C McCoig; M Trujillo; L Wubbel; S Shelton; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

5.  Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.

Authors:  I M Gould; G Harvey; D Golder; T M Reid; S J Watt; J A Friend; J S Legge; J G Douglas
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

Review 6.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

7.  Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.

Authors:  C Ostergaard; T K Sørensen; J D Knudsen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

8.  Timing of penicillin treatment influences the course of Streptococcus pneumoniae-induced middle ear inflammation.

Authors:  K Sato; M K Quartey; C L Liebeler; G S Giebink
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.